Literature DB >> 18173952

The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysis.

Allan D Sniderman1, Robert S Kiss.   

Abstract

The levels of pro- and antiatherogenic lipoproteins are the most important risk factors for vascular disease, and there is now compelling evidence that the apolipoprotein (apo) B/apoA-I ratio is a better index of the likelihood of vascular events than any of the corresponding cholesterol indices: the total cholesterol/high-density lipoprotein cholesterol (HDL-C) ratio, non-HDL-C/HDL-C ratio, or low-density lipoprotein cholesterol (LDL-C)/HDL-C ratio. But are there any restrictions on the application of the apoB/apoA-I ratio to clinical practice? This article suggests that the answer is yes. Based on the available biologic and epidemiologic data, the relation between risk and apoB is continuous, whereas at the extremes of HDL concentration in plasma the relation to risk is not certain. Moreover, LDL plays a causal role in atherogenesis whereas HDL plays a contingent role. Appreciating these distinctions should allow appropriate use of the apoB/apoA-I ratio as a simple, single, summary index of the lipoprotein-related risk of vascular disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18173952     DOI: 10.1007/s11883-007-0031-6

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  33 in total

Review 1.  Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels.

Authors:  S Marcovina; C J Packard
Journal:  J Intern Med       Date:  2006-05       Impact factor: 8.989

2.  The failure of torcetrapib: was it the molecule or the mechanism?

Authors:  Alan R Tall; Laurent Yvan-Charvet; Nan Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-02       Impact factor: 8.311

Review 3.  Apolipoproteins as markers and managers of coronary risk.

Authors:  D C Chan; G F Watts
Journal:  QJM       Date:  2006-02-27

Review 4.  Inherited disorders of HDL metabolism and atherosclerosis.

Authors:  G Kees Hovingh; Eric de Groot; Wim van der Steeg; S Matthijs Boekholdt; Barbara A Hutten; Jan Albert Kuivenhoven; John J P Kastelein
Journal:  Curr Opin Lipidol       Date:  2005-04       Impact factor: 4.776

Review 5.  The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.

Authors:  J A Kuivenhoven; H Pritchard; J Hill; J Frohlich; G Assmann; J Kastelein
Journal:  J Lipid Res       Date:  1997-02       Impact factor: 5.922

Review 6.  Apolipoprotein A-I and risk for cardiovascular diseases.

Authors:  Natalie Khuseyinova; Wolfgang Koenig
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

7.  Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects.

Authors:  Robert S Kiss; Nihan Kavaslar; Kei-ichiro Okuhira; Mason W Freeman; Stephanie Walter; Ross W Milne; Ruth McPherson; Yves L Marcel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-02-15       Impact factor: 8.311

8.  Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.

Authors:  Stephen J Nicholls; E Murat Tuzcu; Ilke Sipahi; Adam W Grasso; Paul Schoenhagen; Tingfei Hu; Kathy Wolski; Tim Crowe; Milind Y Desai; Stanley L Hazen; Samir R Kapadia; Steven E Nissen
Journal:  JAMA       Date:  2007-02-07       Impact factor: 56.272

9.  Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

Authors:  P J Barter; C M Ballantyne; R Carmena; M Castro Cabezas; M John Chapman; P Couture; J de Graaf; P N Durrington; O Faergeman; J Frohlich; C D Furberg; C Gagne; S M Haffner; S E Humphries; I Jungner; R M Krauss; P Kwiterovich; S Marcovina; C J Packard; T A Pearson; K Srinath Reddy; R Rosenson; N Sarrafzadegan; A D Sniderman; A F Stalenhoef; E Stein; P J Talmud; A M Tonkin; G Walldius; K M S Williams
Journal:  J Intern Med       Date:  2006-03       Impact factor: 8.989

10.  Familial hypoalphalipoproteinemia in premature coronary artery disease.

Authors:  J Genest; J M Bard; J C Fruchart; J M Ordovas; E J Schaefer
Journal:  Arterioscler Thromb       Date:  1993-12
View more
  8 in total

Review 1.  Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.

Authors:  Allan Sniderman; Patrick Couture; Jacqueline de Graaf
Journal:  Nat Rev Endocrinol       Date:  2010-04-27       Impact factor: 43.330

2.  Serum Apo A-1 and Its Role as a Biomarker of Coronary Artery Disease.

Authors:  Salma Rahim; Hafez Mohammad A Abdullah; Yousaf Ali; Uzma I Khan; Waqas Ullah; Muhammad A Shahzad; Muhammad Waleed
Journal:  Cureus       Date:  2016-12-24

3.  Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program.

Authors:  Toni I Pollin; Paul W Franks; Tibor V Varga; Alexandra H Winters; Kathleen A Jablonski; Edward S Horton; Prajakta Khare-Ranade; William C Knowler; Santica M Marcovina; Frida Renström; Karol E Watson; Ronald Goldberg; José C Florez
Journal:  Circ Cardiovasc Genet       Date:  2016-10-26

4.  Gender differences in obesogenic behaviour, socioeconomic and metabolic factors in a population-based sample of Iranians: the IHHP study.

Authors:  Ali Akbar Tavassoli; Mojgan Gharipour; Alireza Khosravi; Roya Kelishadi; Zahra Dana Siadat; Ahmad Bahonar; Gholam Hosein Sadri; Masoumeh Sadeghi; Katayoun Rabiei; Firouzeh Sajjadi; Sonia Zarfeshani; Babak Eshrati; Shahin Shirani; Nizal Sarrafzadegan
Journal:  J Health Popul Nutr       Date:  2010-12       Impact factor: 2.000

5.  Coalition of DNA polymorphisms of ApoB and ApoAI genes is related with coronary artery disease in Kazaks.

Authors:  Gang Huang; Hua Zhong; He-Man Re; Hong-Wei Mao; Qiang Niu; Ye-Hong Chi
Journal:  J Geriatr Cardiol       Date:  2012-03       Impact factor: 3.327

6.  Relationship of lipid and lipoprotein ratios with coronary severity in patients with new on-set coronary artery disease complicated with type 2 diabetics.

Authors:  Ying Du; Juan Chen; Man-Hua Chen; Sheng-Hua Yang; Sha Li; Yuan-Lin Guo; Cheng-Gang Zhu; Rui-Xia Xu; Qian Dong; Jian-Jun Li
Journal:  J Geriatr Cardiol       Date:  2016-08       Impact factor: 3.327

7.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.

Authors:  P Emery; E Keystone; H P Tony; A Cantagrel; R van Vollenhoven; A Sanchez; E Alecock; J Lee; J Kremer
Journal:  Ann Rheum Dis       Date:  2008-07-14       Impact factor: 19.103

8.  Sex-specific differences in blood lipids and lipid ratios in type 2 diabetic foot patients.

Authors:  Shuming Yin; Puqing Zhao; Zisheng Ai; Bing Deng; Wei Jia; Huan Wang; Jiaqi Zheng
Journal:  J Diabetes Investig       Date:  2021-07-17       Impact factor: 4.232

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.